Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
U. Costabel (Essen, Germany), S. Shapera (Toronto, Ontario, Canada), S. Tomassetti (Forlì, Italy), T. Baba (Yokohama, Japan), B. Schinzel (Ingelheim am Rhein, Germany), S. Wiebe (Biberach, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Kolb (Hamilton, Ontario, Canada). Safety and pharmacokinetics of nintedanib plus sildenafil in the INSTAGE trial. 1354

Member's Comments

No comment yet.

Related content which might interest you: Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Indacaterol once-daily provides superior efficacy to salmeterol: A 12-week trial Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021 Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021 Safety and tolerability of indacaterol over 52 weeks of treatment in COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2-agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Safety and tolerability of single doses of AZD5069 in healthy volunteers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 An 12-week, Randomised, Parallel-group, Phase III Study comparing the Efficacy of Once-daily Formoterol/Budesonide Turbuhaler 4.5/160 µg and Twice-daily Budesonide Swinghaler 200 µg During Step-down in Well Controlled Asthma Source: International Congress 2017 – Monitoring asthma control Year: 2017